Donidalorsen · Dawnzera

RNA / oligonucleotide

Approvedregulatory verdict

Evidence outlook

Approved: Hereditary Angioedema

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
CH
  • Hereditary angioedema (Dawnzera, donidalorsen); marketing authorisation holder Otsuka Pharmaceutical
Product first approved 2026swissmedic.ch
UK
  • Patients 12 years and older with hereditary angioedema (HAE), to prevent angioedema attacks
Product first approved 2026MHRA
EU
  • Routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older
Product first approved 2026pharmaphorum.com
Featured evidence outside this drug's tracked markets:NCT03263507 · Healthy Volunteers · Phase 1 · completed · ungraded

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Hereditary Angioedema
NCT07298447 · Ionis Pharmaceuticals, Inc.
2026-04-21 – 2029-06 · Hereditary Angioedema (HAE)
What this study did
NCT05392114 · Ionis Pharmaceuticals, Inc.
2022-07-13 – 2027-03 · Hereditary Angioedema
What this study did
Phase 2 (3)
Hereditary Angioedema
NCT04307381 · Ionis Pharmaceuticals, Inc.
2020-03-31 – 2025-01-24 · Hereditary Angioedema
What this study did
Other / comorbidity
NCT04549922 · Hospital do Coracao
2020-10-19 – 2021-12-09 · Covid19
What this study did
Phase 1 (1)
Other / comorbidity
NCT03263507 · Ionis Pharmaceuticals, Inc.
2017-08-28 – 2018-10-09 · Healthy Volunteers
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dawnzera (Donidalorsen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Hereditary AngioedemaActive not recruiting
Est. primary completion 2026-12 · NCT05392114 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
Phase 3Hereditary AngioedemaRecruiting
Est. primary completion 2029-06 · NCT07298447 · CT.gov ↗
What to watch

See the full readout calendar ↗